Page 7 - Shikma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Shikma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Shikma Today - Breaking & Trending Today
Hikma Pharma Issues Trading Update; Announces FDA Approval Of KLOXXADO BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK, HIK.L) said 2021 is off to a good start with performance in line with the Group s expectations. The Group said its full-year outlook is unchanged and it remains confident in ability to deliver consistent long-term, sustainable growth. Separately, Hikma Pharmaceuticals announced the approval of KLOXXADO nasal spray 8mg, by the FDA for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Hikma expects KLOXXADO to be available in the second half of 2021. ....
Hikma Pharma FY20 Profit Down, Lifts Dividend; Stock Down LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK, HIK.L) reported Thursday that its fiscal 2020 profit attributable to shareholders was $431 million, down 11 percent from $486 million last year. Basic earnings per share was 182.6 cents, 9 percent lower than last year s 200.8 cents.. Core profit attributable increased 12 percent to $408 million from $364 million last year. Core earnings per share increased 14 percent to 171.4 cents from 149.8 cents a year ago. Operating profit grew 17 percent to $579 million, and core operating profit went up 11 percent to $566 million, driven by strong growth in profit of Generics and Injectables. Group revenue was $2.34 billion, up 6 percent from $2.21 billion a year ago, reflecting growth in all three businesses. Revenue grew 6 percent at constant currency rates. ....
Hikma Pharmaceuticals said on Tuesday it was planning to buy GSK's stake in some assets including the drugmaker's pharmaceutical, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia. ....
LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK, HIK.L) confirmed Tuesday that it has entered into a non-binding term sheet with GlaxoSmithKline S.A.E. or GSK SAE, the Egyptian subsidiary of ....
(1) Improved rating elevates Hikma to global leadership position LONDON, Jan. 13, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, has received an A- rating from the CDP 2020 Global Climate Change Report, improving on the Group s previous score and elevating Hikma to CDP s Leadership Band of companies implementing current best practices. CDP is an independent, not-for-profit organisation aimed at enabling companies to progress towards environmental stewardship through benchmarking and comparison with peers. In the 2020 report, Hikma received an A rating in five separate categories ranked by CDP, including for its emission reduction initiatives, its scope 1 and 2 emissions (greenhouse gas emissions from direct fuel usage and electricity consumption), its governance and risk management processes, and its business strategy and financial planning. Hikma s performance - with at or above average marks in ....